Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/4-aco-dmt/proposal/contraindication/859279e3-9e37-4811-b566-d2f3099bd23f

proposal2026-04-19recordapproved

derived from · upstream

none recorded

feeds · downstream

Closure of psx:substance/4-aco-dmt/proposal/contraindication/859279e3-9e37-4811-b566-d2f3099bd23f: 0 upstream, 1 downstream.

psx:substance/4-aco-dmt/proposal/contraindication/859279e3-9e37-4811-b566-d2f3099bd23f
└─ derived_from  value/contraindication/f4e88d72-1740-4817-aee6-125f954fc812@1

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

2724 with DOI

16 strong · 9 moderate · 2 weak

Compilations

0no compilation run

Decisions

42last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:29:50.217Z

notice · info card · emergency

Searches

00 with no results

queries and counts on the build

Claims checked

6832 supported

32 supported · 36 not

Correspondence

0received

consent field ships in Phase 4

Edges

213

derivations recorded for this entity

Complete over 27 sources and 42 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/4-aco-dmt/archive

3Sources

27 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
20265-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuationWang Y, Yao Y, Su R, Yan H · British Journal of Pharmacologydoi:10.1111/bph.70307moderateconsumed1 section
2026In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocinJurowski K, Kobylarz D, Noga M · Archives of Toxicologydoi:10.1007/s00204-026-04365-4moderateconsumed2 sections
2026Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive SubstancesRached G, Campana A, Fiani D, et al. · CNS Drugsdoi:10.1007/s40263-025-01256-7strongconsumed1 section
2025Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc AnalysisOtto ME, van der Heijden KV, Schoones JW, et al. · Clinical Pharmacokineticsdoi:10.1007/s40262-024-01454-4strongconsumed2 sections
2025Elucidating the Phase I metabolism of psilocin in vitroChen J, Wang Z, Yong CY, et al. · Archives of Toxicologydoi:10.1007/s00204-024-03952-7moderateconsumed3 sections
2025Pharmacokinetics of Psilocybin: A Systematic ReviewMeshkat S, Al-Shamali H, Perivolaris A, et al. · Pharmaceuticsdoi:10.3390/pharmaceutics17040411strongconsumed2 sections
2025The polypharmacology of psychedelics reveals multiple targets for potential therapeuticsJain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL · Neurondoi:10.1016/j.neuron.2025.06.012strongconsumed2 sections
20244-AcO-DMTWikipedia contributorsurl:946c31199207c835weakconsumedcited only
2024In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybinJones NT, Wagner L, Hahn MCP, Scarlett CO, Wenthur CJ · Frontiers in Psychiatrydoi:10.3389/fpsyt.2023.1303365strongconsumed5 sections
2024Rewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process TheoryVargas-Perez H, Minauro-Sanmiguel F, Ting-A-Kee R, Grieder TE, Méndez-Díaz M, Próspero-García O, van der Kooy D · Neuroscience Lettersdoi:10.1016/j.neulet.2023.137597strongconsumed2 sections
2023A non-hallucinogenic LSD analog with therapeutic potential for mood disordersLewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, Calkins MM, Bautista-Carro MA, Arsenault E, Telfer A, Taghavi-Abkuh FF, Malcolm NJ, El Sayegh F, Abizaid A, Schmid Y, Morton K, Halberstadt AL, Aguilar-Valles A, McCorvy JD · Cell Reportsdoi:10.1016/j.celrep.2023.112203strongconsumed1 section
2023Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial CellsRobinson GI, Li D, Wang B, Zahoruiko Y, Gerasymchuk M, Hudson D, Kovalchuk O, Kovalchuk I · Current Issues in Molecular Biologydoi:10.3390/cimb45080427moderateconsumedcited only
2023Psilocin - The 'real deal' or an extraction byproductGutman O, Tenne D, Bretler U · Journal of Forensic Sciencesdoi:10.1111/1556-4029.15167moderateconsumed1 section
2023Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal TissueRobinson GI, Li D, Wang B, Rahman T, Gerasymchuk M, Hudson D, Kovalchuk O, Kovalchuk I · Lifedoi:10.3390/life13122345moderateconsumed1 section
2023Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in MiceGlatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, Baumann MH · ACS Pharmacology & Translational Sciencedoi:10.1021/acsptsci.2c00222strongconsumed5 sections
2022Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in MiceGlatfelter GC, Pottie E, Partilla JS, Sherwood AM, et al. · ACS Pharmacology and Translational Sciencedoi:10.1021/acsptsci.2c00177moderateconsumed5 sections
2022Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MSZhai W, Li L, Zhao J, Xiang P, Liu M, Shi Y, Dang Y · Drug Testing and Analysisdoi:10.1002/dta.3255strongconsumed5 sections
2020Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7strongconsumed1 section
2020Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin ReceptorKim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL · Celldoi:10.1016/j.cell.2020.08.024strongconsumed1 section
2019Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrugChadeayne AR, Golen JA, Manke DR · Acta Crystallographica Section E Crystallographic Communicationsdoi:10.1107/s2056989019007370strongconsumed2 sections
2018Chemistry and Structure-Activity Relationships of Psychedelics.Nichols DE · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2017_475strongconsumed3 sections
2018Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic PerspectivesMartinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, Di Giannantonio M, Gallimberti L · Brain Sciencesdoi:10.3390/brainsci8030047moderateconsumed1 section
2017A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy SubjectsDolder PC, Grünblatt E, Müller F, Borgwardt SJ, Liechti ME · Frontiers in Pharmacologydoi:10.3389/fphar.2017.00423strongconsumed1 section
20164-AcO-DMT (Psilacetin) - Erowid BasicsErowidurl:7a90964f24ed4f5dweakconsumedcited only
2016Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogensRickli A, Moning OD, Hoener MC, Liechti ME · European Neuropsychopharmacologydoi:10.1016/j.euroneuro.2016.05.001strongconsumed1 section
2005Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.Gillman PK · British Journal of Anaesthesiapmid:16051647strongconsumed1 section
1999Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of PsilocinNichols DE, Frescas S · Synthesisdoi:10.1055/s-1999-3490moderateconsumed3 sections

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-04-19revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki)

    psx:substance/4-aco-dmt/version/1
  2. 0022026-06-04proposal40 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    40 items in this filing

    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • timeline · insufflated · onset
    • timeline · insufflated · come_up
    • timeline · insufflated · peak
    • timeline · insufflated · resolution
    • timeline · insufflated · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • dosage · insufflated
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    • duration · insufflated · onset
    • duration · insufflated · come_up
    • duration · insufflated · peak
    • duration · insufflated · offset
    • duration · insufflated · total
    • duration · insufflated · aftereffects
    • contraindication · psychiatric
    • contraindication · psychiatric
    • contraindication · other
    • contraindication · other
    • contraindication · cardiovascular
    • contraindication · neurological
    • contraindication · pregnancy_breastfeeding
    psx:substance/4-aco-dmt/proposal/dose_tier/343ef73e-f797-4471-b512-4c292aa90f76
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/4-aco-dmt/pub/9aa9e7e9-e7aa-40c4-b484-d5fa3248e35f

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
emergencyc15c760aabf6f0fcf5b6fc6b…2026-10-19 20:29Revision 1current
info_card017f70fc6826ea42f871be74…2026-10-19 20:29Revision 1current
notice9a96b1160ba9098f7cde020c…2026-10-19 20:29Revision 1current
emergency3f0909c25c714d225b4bb3e3…2026-09-04 04:27Revision 1superseded2026-10-19
info_card2b6c0a7b280ef371daca87c7…2026-09-04 04:27Revision 1superseded2026-10-19
noticeb90cab31cadf5bd920a3dc6c…2026-09-04 04:27Revision 1superseded2026-10-19